Ubivac
Portland, US · Delaware corporation
UbiVac is a clinical-stage cancer immunotherapy and target-discovery company developing off-the-shelf combination vaccines, including its lead agent DPV-001, based on "Dark Genome"-derived non-mutated shared cancer neoantigens. Its therapies are being tested in first-in-human trials for cancers such as head and neck squamous cell carcinoma and non-small cell lung cancer, with the company also applying machine learning to discover novel cancer targets.
Founders & leadership
HH
Hong-Ming Hu, Ph.D.Co-founder
BA
Bernard A. FoxinCo-founder & CEO
BA
Bernard A. Fox, IIIExecutive
BF
Bernard Fox, Ph.D.Named on SEC filing
BA
Bernard A. Fox III, MBANamed on SEC filing
Board
SP
Sung Poblete, R.N., Ph.D.Board director
Reported raises · per SEC filings
Form D private placements$2.8M disclosed across 7 rounds · 2017–2026
▶$80KraisedAug 2026 · 2 investors · BiotechnologyRule 506(b)
▶$80KraisedAug 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bernard Fox, Ph.D.Executive Officer, Director
- Hong-Ming Hu, Ph.D.Executive Officer, Director
- Bernard A. Fox, IIIExecutive Officer
- Sung Poblete, R.N., Ph.D.Director
- Amount sold
- $80K
- Minimum investment
- $10K
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35KraisedMar 2025 · 2 investors · BiotechnologyRule 506(b)
▶$35KraisedMar 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bernard Fox, Ph.D.Executive Officer, Director
- Bernard A. Fox, IIIExecutive Officer
- Hong-Ming Hu, Ph.D.Executive Officer, Director
- Sung Poblete, R.N., Ph.D.Director
- Offering amount
- $4.5M
- Amount sold
- $35K
- Minimum investment
- $10K
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$150KraisedSep 2024 · 3 investors · BiotechnologyRule 506(c)
▶$150KraisedSep 2024 · 3 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Hong-Ming Hu, Ph.D.Executive Officer, Director
- Bernard A. Fox, IIIExecutive Officer
- Bernard Fox, Ph.D.Executive Officer, Director
- Sung Poblete, R.N., Ph.D.Director
- Amount sold
- $150K
- Minimum investment
- $25K
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$100KraisedNov 2023 · 2 investors · BiotechnologyRule 506(b)
▶$100KraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nancy LimeExecutive Officer
- Bernard A. Fox, IIIExecutive Officer
- Bernard Fox, Ph.D.Executive Officer, Director
- Sung Poblete, R.N., Ph.D.Director
- Hong-Ming Hu, Ph.DExecutive Officer, Director
- Amount sold
- $100K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedApr 2022 · 1 investors · BiotechnologyRule 506(c)
▶$250KraisedApr 2022 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Bernard A. Fox, Ph.D.Executive Officer, Director
- Steve BuhalyExecutive Officer
- Bernard Fox, MBAExecutive Officer
- Jon Wigginton, M.D.Director
- Nancy LimeExecutive Officer
- Hong-Ming Hu, Ph.D.Executive Officer, Director
- Offering amount
- $5M
- Amount sold
- $250K
- Minimum investment
- $250K
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$1.9MraisedApr 2019 · 10 investors · BiotechnologyRule 506(b)
▶$1.9MraisedApr 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bernard A. Fox, MBAExecutive Officer
- Hong-Ming Hu, Ph.DExecutive Officer
- Steve BuhalyExecutive Officer
- Bernard Fox, Ph.DExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.9M
- Minimum investment
- $100K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedAug 2017 · 2 investors · PharmaceuticalsRule 506(b)
▶$200KraisedAug 2017 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Bernard A. Fox III, MBAExecutive Officer
- Hong-Ming Hu, Ph.DExecutive Officer
- Bernard Fox, Ph.DExecutive Officer
- Offering amount
- $2M
- Amount sold
- $200K
- Minimum investment
- $100K
- First sale
- Jul 2017
- Incorporated
- Limited Liability Company, Oregon
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Ubivac for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $288.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2009 | $3.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $152.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Ubivac do?
- UbiVac is a clinical-stage cancer immunotherapy and target-discovery company developing off-the-shelf combination vaccines, including its lead agent DPV-001, based on "Dark Genome"-derived non-mutated shared cancer neoantigens. Its therapies are being tested in first-in-human trials for cancers such as head and neck squamous cell carcinoma and non-small cell lung cancer, with the company also applying machine learning to discover novel cancer targets.
- Who founded Ubivac?
- Ubivac was founded by Hong-Ming Hu, Ph.D., Bernard A. Fox.
- How much funding has Ubivac raised?
- Ubivac has disclosed $2.8M raised across 7 rounds.
- Where is Ubivac headquartered?
- Ubivac is headquartered in Portland, US.